![Knight Therapeutics Inc. logo](/logos/GUD.TO.webp)
Knight Therapeutics Inc.
TSX:GUD.TO
Overview | Financials
Company Name | Knight Therapeutics Inc. |
Symbol | GUD.TO |
Currency | CAD |
Price | 5.64 |
Market Cap | 570,846,960 |
Dividend Yield | 0% |
52-week-range | 4.35 - 6.22 |
Industry | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Ms. Samira Sakhia BCom, CA, CPA, MBA |
Website | https://www.gud-knight.com |
An error occurred while fetching data.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD